Institution
University of Oviedo
Education•Oviedo, Spain•
About: University of Oviedo is a education organization based out in Oviedo, Spain. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 13423 authors who have published 31649 publications receiving 844799 citations. The organization is also known as: Universidá d'Uviéu & Universidad de Oviedo.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Deep RNA sequencing in different subpopulations of normal B-lymphocytes and CLL cells from a cohort of 98 patients characterized the CLL transcriptional landscape with unprecedented resolution, and found genes related to spliceosome, proteasome, and ribosome were among the most down-regulated in CLL.
Abstract: Chronic lymphocytic leukemia (CLL) has heterogeneous clinical and biological behavior. Whole-genome and -exome sequencing has contributed to the characterization of the mutational spectrum of the disease, but the underlying transcriptional profile is still poorly understood. We have performed deep RNA sequencing in different subpopulations of normal B-lymphocytes and CLL cells from a cohort of 98 patients, and characterized the CLL transcriptional landscape with unprecedented resolution. We detected thousands of transcriptional elements differentially expressed between the CLL and normal B cells, including protein-coding genes, noncoding RNAs, and pseudogenes. Transposable elements are globally derepressed in CLL cells. In addition, two thousand genes—most of which are not differentially expressed—exhibit CLL-specific splicing patterns. Genes involved in metabolic pathways showed higher expression in CLL, while genes related to spliceosome, proteasome, and ribosome were among the most down-regulated in CLL. Clustering of the CLL samples according to RNA-seq derived gene expression levels unveiled two robust molecular subgroups, C1 and C2. C1/C2 subgroups and the mutational status of the immunoglobulin heavy variable (IGHV) region were the only independent variables in predicting time to treatment in a multivariate analysis with main clinico-biological features. This subdivision was validated in an independent cohort of patients monitored through DNA microarrays. Further analysis shows that B-cell receptor (BCR) activation in the microenvironment of the lymph node may be at the origin of the C1/C2 differences.
188 citations
••
TL;DR: In this article, the authors presented a measurement of the inclusive jet cross section in p-pbar collisions at sqrt{s}=1.96 TeV based on data collected by the CDF II detector with an integrated luminosity of 1.13 fb^-1.1
Abstract: We present a measurement of the inclusive jet cross section in p-pbar collisions at sqrt{s}=1.96 TeV based on data collected by the CDF II detector with an integrated luminosity of 1.13 fb^-1. The measurement was made using the cone-based Midpoint jet clustering algorithm in the rapidity region of |y|<2.1. The results are consistent with next-to-leading-order perturbative QCD predictions based on recent parton distribution functions (PDFs), and are expected to provide increased precision in PDFs at high parton momentum fraction x. The results are also compared to the recent inclusive jet cross section measurement using the k_T jet clustering algorithm, and we find that the ratio of the cross sections measured with the two algorithms is in agreement with theoretical expectations over a large range of jet transverse momentum and rapidity.
188 citations
••
TL;DR: In this article, the first study of isolated photon + jet correlations in relativistic heavy ion collisions is reported using data from PbPb collisions at a centre-of-mass energy of 2.76 TeV2.
188 citations
••
TL;DR: The present review aims at summarizing the current knowledge on intestinal microbiota alterations and other functions impaired in the elderly and to analyze tools for implementing nutritional strategies, through the use of probiotics, prebiotics or specific nutrients in order to counterbalance such alterations.
Abstract: The gut microbiota is the assembly of microorganisms living in our intestine and their genomes are known as the microbiome. The correct composition and functionality of this microbiome is essential for maintaining a "healthy status." Aging is related to changes in the gut microbiota which are frequently associated with physiological modifications of the gastrointestinal tract, as well as, to changes in dietary patterns, together with a concomitant decline in cognitive and immune function, all together contributing to frailty. Therefore, nutritional strategies directed at restoring the microbiota in the elderly have to be addressed from a global perspective, considering not only the microbiota but also other extra-intestinal targets of action. The present review aims at summarizing the current knowledge on intestinal microbiota alterations and other functions impaired in the elderly and to analyze tools for implementing nutritional strategies, through the use of probiotics, prebiotics or specific nutrients in order to counterbalance such alterations.
188 citations
••
TL;DR: Subcutaneous canakinumab 150 mg every 8 weeks was well tolerated and provided substantial disease control in children and adults across all CAPS phenotypes.
Abstract: Objective Longer-term effects of prolonged selective interleukin-1β blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date. Methods Adult and paediatric CAPS patients (n=166, including canakinumab-naive and pretreated patients from previous studies) received canakinumab subcutaneously 150 mg or 2 mg/kg (≤40 kg) every 8 weeks for up to 2 years. Response and relapse was assessed using scores for disease activity, skin rash and C-reactive protein (CRP) and/or serum amyloid A (SAA) levels. Results Complete response was achieved in 85 of 109 canakinumab-naive patients (78%; 79/85 patients within 8 days, and five patients between days 10 and 21). Of 141 patients with an available relapse assessment, 90% did not relapse, their CRP/SAA levels normalised ( Conclusions Subcutaneous canakinumab 150 mg every 8 weeks was well tolerated and provided substantial disease control in children and adults across all CAPS phenotypes. Higher canakinumab doses in younger patients and more severe CAPS disease were efficacious in achieving complete responses without evidence of increased AE. Trial registration number: NCT00685373 (clinicaltrials.gov)
188 citations
Authors
Showing all 13643 results
Name | H-index | Papers | Citations |
---|---|---|---|
Russel J. Reiter | 169 | 1646 | 121010 |
Carlo Rovelli | 146 | 1502 | 103550 |
J. González-Nuevo | 144 | 500 | 108318 |
German Martinez | 141 | 1476 | 107887 |
Roland Horisberger | 139 | 1471 | 100458 |
Francisco Herrera | 139 | 1001 | 82976 |
Javier Cuevas | 138 | 1689 | 103604 |
Teresa Rodrigo | 138 | 1831 | 103601 |
L. Toffolatti | 136 | 376 | 95529 |
Elias Campo | 135 | 761 | 85160 |
Gabor Istvan Veres | 135 | 1349 | 96104 |
Francisco Matorras | 134 | 1428 | 94627 |
Joe Incandela | 134 | 1549 | 93750 |
Nikhil C. Munshi | 134 | 906 | 67349 |
Luca Scodellaro | 134 | 1741 | 98331 |